Optimizing the Dose and Duration of Therapy for ChronicHepatitis C

Pichetshote, Nipaporn; Groessl, Erik J.; Yee, Helen S.; Ho, Samuel B.

doi:10.5009/gnl.2009.3.1.1

Cited by 2 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, we mainly focused on pretreatment factors that might predict a treatment response. On‐treatment factors, such as the rapid virological response (RVR), are gaining importance in guiding further therapy 24 . In this study, the RVR assessment was not done for many patients, because many patients underwent therapy before the introduction of the RVR.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Sinn

Shin

Kil

et al. 2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Sinn

Shin

Kil

et al. 2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In the present study, 72.3% patients achieved RVR. Previous studies have reported an RVR rate of 62-68% in genotype 2/3 infected patients, 1,20 while a higher (71-93%) RVR rate has been reported in studies using weight based ribavirin. 20 With a standard 24 week course of therapy, SVR rate of 80-91% has been reported in RVR achievers whereas RVR non-achievers have 36-62% SVR rate.…”

Section: Discussionmentioning

confidence: 85%

“…Previous studies have reported an RVR rate of 62-68% in genotype 2/3 infected patients, 1,20 while a higher (71-93%) RVR rate has been reported in studies using weight based ribavirin. 20 With a standard 24 week course of therapy, SVR rate of 80-91% has been reported in RVR achievers whereas RVR non-achievers have 36-62% SVR rate. [8][9][10][11][12]20 Similar results were noted in the present study where the SVR rates with standard 24 week therapy in RVR achievers and RVR non-achievers were 91.5% and 52.3% respectively.…”

Section: Discussionmentioning

confidence: 85%

“…20 With a standard 24 week course of therapy, SVR rate of 80-91% has been reported in RVR achievers whereas RVR non-achievers have 36-62% SVR rate. [8][9][10][11][12]20 Similar results were noted in the present study where the SVR rates with standard 24 week therapy in RVR achievers and RVR non-achievers were 91.5% and 52.3% respectively. These data emphasize the need for extended therapy in CHC G3 patients who do not achieve RVR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response

Sood

Midha

2015

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Background/Objectives: Chronic hepatitis C (CHC) genotype-3 (G-3) patients treated with standard 24-week pegylated interferon plus ribavirin(PEG-RBV) therapy achieve sustained virological response(SVR) rate of 69-82%. Patients who do not achieve rapid virological response(RVR) have lower SVR rate. Data regarding optimal management of this subgroup is scarce. We aimed to determine the most appropriate treatment duration in CHC G-3 patients who do not achieve RVR. Methods: Treatment na € õve CHC G-3 patients treated with PEG-RBV therapy were included in this retrospective analysis. Patients with cirrhosis were excluded. RVR was assessed in all patients beyond the year 2007. RVR non-achievers were advised extended treatment beyond 24 weeks. Results: Of the total 685 patients started on treatment, 646 completed treatment (mean age 39.1 ± 12 years, 68.3% males). In the pre-'RVR assessment ' period (2004-2006), SVR with standard 24 week therapy was 72.3% (112/155). In post-'RVR assessment ' period (2007-2013), 75.8% (402/530) patients achieved RVR; and 91.5% (368/402) of these achieved SVR with standard 24 weeks therapy. Among RVR non-achievers (n = 128), 51 patients opted for extended 36 week therapy, 12 for 48 week therapy, while 65 stopped therapy at 24 weeks. Choice of treatment duration was dependent entirely on the affordability of the patient. SVR with extended therapy (36/48 weeks) was significantly higher than standard 24 week therapy in RVR non-achievers (82.5% vs. 52.3%; P = 0.003). However, SVR rate in 36 week group was not significantly different from 48 week group (84.3% vs. 75%; P = 0.425]. On multivariate analysis, duration of treatment (36/48 week vs. 24 week; P < 0.001) was significantly associated with SVR. Conclusions: SVR rates in CHC G-3 patients treated with PEG-RBV in northern India were comparable to western data. Standard 24 week therapy is adequate for RVR-achievers. However, in RVR non-achievers, extended 36 week therapy significantly improves SVR, while further extension to 48 week does not provide any additional advantage. ( J CLIN EXP HEPATOL 2015;5:2-7)

show abstract

Optimizing the Dose and Duration of Therapy for ChronicHepatitis C

Cited by 2 publications

References 52 publications

Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Efficacy of peg‐interferon‐α‐2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea

Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response

Contact Info

Product

Resources

About